Company intelligence / Profile preview

Heptares Therapeutics

Welwyn Garden City, Hertfordshire, United Kingdomheptares.com ↗

Ownership: Public · 4565
Employees: ~150
Development stage: Other

Overview

Heptares has built a pipeline of novel medicines targeting historically undruggable or challenging GPCRs using its proprietary StaR® technology. The company has advanced candidates into clinical development for CNS disorders and immuno-oncology. It has established major partnerships with leading pharmaceutical companies to further develop and commercialize its discoveries.

Therapeutic areas: PsychiatryMetabolic DisordersOncologyRare DiseasesNeurology
Modalities: Small moleculesbiologics (including antibody therapeutics derived from StaR antigens)
Industry: Biotech

Partnerships

Pfizer Inc.AstraZeneca/MedImmune/Cubist Pharmaceuticals/MorphoSys/Takeda Pharmaceuticals

Beyond the preview

Go deeper on Heptares Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heptares Therapeutics.